MA-FORRESTER
5.2.2024 15:01:26 CET | Business Wire | Press release
Forrester (Nasdaq: FORR) today opened calls for nominations for its 2024 global Technology Awards in two categories: Technology Strategy Impact and Enterprise Architecture. These awards recognize organizations that align their technology strategies to their business goals, are quick to adapt to changing market conditions, and focus on building customer trust. Strong alignment is critical to business results: According to Forrester, firms with strong alignment grow 2.4 times faster than peers and have twice the profitability.
Nomination criteria for Forrester’s Technology Awards are as follows:
- Technology Strategy Impact. Award recipients must execute a high-performance IT strategy, which Forrester defines as the pursuit of continuous improvement of business results through technology. Recipients must also demonstrate how they use alignment, trust, and adaptivity to enhance business outcomes with their IT capabilities.
- Enterprise Architecture. This award, presented in partnership with The Open Group — author of the TOGAF® standard, developed by The Open Group Architecture Forum — recognizes organizations that demonstrate how their outcome-driven enterprise architecture (EA) practice fuels change, growth, and differentiation. Organizations must also show how their EA practice helps their firm manage risk, drive cost efficiency, improve customer experience, and increase revenue.
Nominations for both award categories are open to organizations with 1,000 or more employees that are using technology to improve business outcomes. Technology leaders — including chief information officers, chief technology officers, chief digital officers, and enterprise architects across North America; Europe, the Middle East, and Africa (EMEA); and Asia Pacific (APAC) — are encouraged to apply.
Additional details on how to apply for Forrester’s 2024 Technology Awards:
- North America. Organizations in North America can visit here, with an awards submission deadline of May 20, 2024. Award recipients will be announced prior to and honored at Forrester’s Technology & Innovation Summit North America, being held in Austin, Texas, and digitally, September 9–12, 2024.
- EMEA. Organizations in EMEA can visit here, with an awards submission deadline of June 20, 2024. Award recipients will be announced prior to and honored at Forrester’s Technology & Innovation Summit EMEA, being held in London and digitally, October 9–11, 2024.
- Asia Pacific. Organizations in APAC can visit here, with an awards submission deadline of July 9, 2024. Award recipients will be announced prior to and honored at Forrester’s Technology & Innovation Summit APAC, being held in Sydney and digitally, October 29, 2024.
“Forrester’s Technology Awards will honor organizations that continually pursue the improvement of business results through technology,” said Laura Koetzle, vice president and group research director at Forrester. “These organizations embody the three guiding principles of high-performance IT strategy: alignment, trust, and adaptivity.”
“Enterprise architecture plays a critical role in driving growth and making a tangible difference in business outcomes. By identifying and describing the future and current state of the enterprise, EA provides one of the most effective ways to realize the organization’s objectives. Recognizing and celebrating EA practices and initiatives around the world has never been more important,” said Steve Nunn, president and CEO of The Open Group.
Resources:
- Learn more about Forrester’s 2024 Technology Awards program.
- Register to attend Forrester’s Technology & Innovation Summits 2024 in North America, EMEA, and APAC.
About Forrester
Forrester (Nasdaq: FORR) is one of the most influential research and advisory firms in the world. We help leaders across technology, customer experience, digital, marketing, sales, and product functions use customer obsession to accelerate growth. Through Forrester’s proprietary research, consulting, and events, leaders from around the globe are empowered to be bold at work — to navigate change and put their customers at the center of their leadership, strategy, and operations. Our unique insights are grounded in annual surveys of more than 700,000 consumers, business leaders, and technology leaders worldwide; rigorous and objective research methodologies, including Forrester Wave™ evaluations; more than 100 million real-time feedback votes; and the shared wisdom of our clients. To learn more, visit Forrester.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240205913561/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom